Suchergebnisse
What Makes Bank7 (BSVN) a New Strong Buy Stock
Bank7 (BSVN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of
What Makes Diamondback (FANG) a New Buy Stock
Diamondback Energy (FANG) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates --
John Wiley & Sons (WLY) Upgraded to Strong Buy: Here's What You Should Know
John Wiley & Sons (WLY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces
Credo Technology Group (CRDO) Upgraded to Strong Buy: Here's Why
Investors might want to bet on Credo Technology Group Holding Ltd. (CRDO), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in
All You Need to Know About Viper Energy (VNOM) Rating Upgrade to Buy
Viper Energy Partners (VNOM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings
All You Need to Know About Life Time Group Holdings (LTH) Rating Upgrade to Buy
Life Time Group Holdings, Inc. (LTH) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings
Chewy (CHWY) Upgraded to Strong Buy: Here's What You Should Know
Investors might want to bet on Chewy (CHWY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of
All You Need to Know About StoneX Group (SNEX) Rating Upgrade to Strong Buy
StoneX Group Inc. (SNEX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which
All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy
CareDx (CDNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the
Nordson (NDSN) is an Incredible Growth Stock: 3 Reasons Why
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to
Alphabet Shares Rise 7% YTD: Buy, Sell, or Hold the GOOGL Stock?
Alphabet GOOGL shares have returned 7.4% year to date (YTD), outperforming the Zacks Computer & Technology sector’s 4.1%. The company’s prospects are expected to benefit from its growing AI-powered
NextEra Energy vs. Duke Energy: Which Utility Stock Has Better Upside?
The Zacks Utility - Electric Power industry presents a compelling case for stable, long-term income due to its regulated nature. This framework allows utilities to recover costs and earn steady
Why Integra (IART) is Poised to Beat Earnings Estimates Again
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Integra LifeSciences (IART), which
Why Huron Consulting (HURN) Could Beat Earnings Estimates Again
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Huron
Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Henry Schein (HSIC), which belongs to
Can Huntington Ingalls (HII) Keep the Earnings Surprise Streak Alive?
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Huntington
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study
Eli Lilly and Company LLY announced that a phase III study, ACHIEVE-4, evaluating its newly approved oral GLP-1 weight-loss pill Foundayo (orforglipron), for treating patients with type II diabetes
ISRG's Rising Procedure TAM With Low Penetration Backs Sustained Growth
Intuitive Surgical’s ISRG expanding “line-of-sight” procedure opportunity underscores a compelling long-term growth runway. Management highlighted that identifiable procedures suitable for its


